WC3 reassortant vaccines in children

Brief review
  • H. F. Clark
  • P. A. Offit
  • R. W. Ellis
  • D. Krah
  • A. R. Shaw
  • J. J. Eiden
  • M. Pichichero
  • J. J. Treanor
Part of the Archives of Virology book series (ARCHIVES SUPPL, volume 12)


Bovine rotavirus strain WC3 (P7[5], G6) administered at the 12th passage level was well tolerated clinically in infants and efficiently induced serum virus neutralizing antibody (VNA) with bovine rotavirus G6 specificity. The protective efficacy of WC3 vaccine against all rotavirus disease was inconsistent, varying in four separate trials from 76% to 0%; some selective protection against severe disease was seen in all trials. WC3 reassortants containing the gene for an individual human rotavirus VP7 (G) or VP4 (P) surface antigen were also well tolerated, but preferentially induced VNA to the WC3 parent. Efficacy trials of human G1 VP7 reassortant WI79-9 (P7[5], G1) consistently led to >60% protection against all rotavirus disease. A quadrivalent WC3 reassortant vaccine was developed to contain four separate monovalent reassortants expressing human rotaviruses surface proteins G1, G2, G3, and P1A [8] respectively. In a multicenter trial including 439 infants, this vaccine induced 67.1% protection against all rotavirus disease (defined as positive for rotavirus antigen by ELISA only [p= <0.001]) and 72.6% protection when the standard for rotavirus diagnosis was a positive test of stool for both rotavirus antigen by ELISA and rotavirus RNA by electropherotype analysis (p = < 0.001). In this trial, episodes of the most severe rotavirus disease (clinical severity score > 16.0, eight cases) occurred only in placebo recipients.


Virus Neutralize Antibody Reassortant Vaccine Virus Neutralize Antibody Response 12th Passage Level Rota Virus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Acres DS, Radostits OM (1976) The efficacy of a modified live reo-like virus vaccine and an E. coli bacteria for prevention of acute neonatal diarrhea of beef calves. Can Vet J 17: 197–212PubMedGoogle Scholar
  2. 2.
    Bernstein DI, Smith VE, Sander DS, Pax KS, Schiff GM, Ward RL (1990) Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 162: 1055–1062PubMedCrossRefGoogle Scholar
  3. 3.
    Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA (1995) Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in U.S. Children. J Amer Med Assoc 273: 1191–1196CrossRefGoogle Scholar
  4. 4.
    Bishop RF, Davidson GP, Holmes H, Ruck BJ (1973) Virus particles in epithelial cells of duodenal mucosa from children with viral gastroenteritis. Lancet 2: 1281–1283PubMedCrossRefGoogle Scholar
  5. 5.
    Christy C, Madore HP, Treanor JJ, Pray K, Kapikian AZ, Chanock RM, Dolin R (1986) Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine. J Infect Dis 154: 1045–1047PubMedCrossRefGoogle Scholar
  6. 6.
    Clark HF, Furukawa T, Bell LM, Offit PA, Perrella PA, Plotkin SA (1986) Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Amer J Dis Children 140: 350–356Google Scholar
  7. 7.
    Clark HF, Borian EF, Bell LM, Modesto K, Gouvea V, Plotkin SA (1988) Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 158: 750–587CrossRefGoogle Scholar
  8. 8.
    Clark HF, Borian FE, Modesto K, Plotkin SA (1990a) Serotype 1 reassortant of bovine rotavirus WC3, strain WI79-9, induces a polytypic antibody response in infants. Vaccine 8: 327–332PubMedCrossRefGoogle Scholar
  9. 9.
    Clark HF, Borian FE, Plotkin SA (1990b) Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. J Infect Dis 161: 1099–1104PubMedCrossRefGoogle Scholar
  10. 10.
    Clark HF, Offit PA (1994) Rotavirus vaccines. In: Plotkin SA, Mortimer EA (eds) Vaccines. Saunders, Philadelphia, pp 809–822Google Scholar
  11. 11.
    Clark HF, Welsko D, Offit PA (1992) Infant responses to bovine WC3 reassortants containing human rotavirus VP7, VP4, or VP7 & VP4. ICAAC Anaheim, p 343Google Scholar
  12. 12.
    Clark HF, White CJ, Offit PA, Stinson D, Eiden J, Weaver S, Cho I, Shaw A, Krah D, Ellis R + OHBRV Study Group (1995) Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine. Ped Res 37: 172AGoogle Scholar
  13. 13.
    Delem A, Lobmann M, Zygraich N (1984) A bovine rotavirus developed as a candidate vaccine for use in humans. J Biol Stand 12: 443–445PubMedCrossRefGoogle Scholar
  14. 14.
    Estes MK, Graham DY, Petrie BL (1985) Antigenic structure of rotaviruses. In: van Regenmortel MHV, Neurath AR (eds) Immunochemistry of viruses. Elsevier, Amsterdam, pp 389–405Google Scholar
  15. 15.
    Estes MK (1996) Rotaviruses and their replication. In: Fields BN et al. (eds) Virology. Lippincott-Raven Publishers, New York, pp 1625–1655Google Scholar
  16. 16.
    Garbag-Chenon A, Fontaine J-L, Lasfargues G, Clark HF, Guyot J, LeMoing G, Hessel L, Bricout F (1989) Reactogenicity and immunogenicity of rotavirus WC3 vaccine in 5-12 month old infants. Res Virol 140: 207–217PubMedCrossRefGoogle Scholar
  17. 17.
    Georges-Courbot MC, Monges J, Siopathis MR, Roungou JP, Gresenguet G, Bellec L, Bouquety JC, Lanckviet C, Cadoz M, Hessel L, Gouvea G, Clark HF, Georges AJ (1991) Evaluation of the efficacy of a low passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 142: 405–411PubMedCrossRefGoogle Scholar
  18. 18.
    Hoshino Y, Wyatt RG, Greenberg HB, Flores J, Kapikian AZ (1984) Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization. J Infect Dis 149: 694–702PubMedCrossRefGoogle Scholar
  19. 19.
    Institute of Medicine (1986) The prospects for immunzing against rotavirus. In: New vaccine development. Establishing priorities. Diseases of importance in developing countries, vol II. National Academy Press, Washington, DC, pp 308–318Google Scholar
  20. 20.
    Kobayashi M, Thompson J, Tottlefson SJ, Reed GW, Wright PF (1994) Tetravalent rhesus rotavirus vaccine in young infants. J Infect Dis 170: 1260–1263PubMedCrossRefGoogle Scholar
  21. 21.
    Mebus CA, Underdahl NR, Rhodes MB, Twiehaus MJ (1969) Calf diarrhea (Scours): reproduced with a virus from a field outbreak. Nebraska Res Bull 233. Nebraska Agricultural Experiment Station, Lincoln, NebraskaGoogle Scholar
  22. 22.
    Mebus CA, White RG, Stair FL, Rhodes MB, Twiehaus MJ (1972) Neonatal calf diarrhea: results of a field trial using a reo-like virus vaccine. Vet Med Ann Clin 67: 173–174Google Scholar
  23. 23.
    Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM (1985) Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 53: 949–954PubMedGoogle Scholar
  24. 24.
    Treanor JJ, Clark HF, Pichichero M, Christy C, Gouvea V, Shrager D, Palazzo S, Offit PA (1995) Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatric Infect Dis J 14: 301–397CrossRefGoogle Scholar
  25. 25.
    Ward RL, Sander DS, Schiff GM, Bernstein DI (1990) Effect of vaccination on serotype-specific antibody responses in infants administered WC3 bovine rotavirus before or after a natural rotavirus infection. J Infect Dis 162: 1298–1303PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1996

Authors and Affiliations

  • H. F. Clark
    • 1
    • 4
  • P. A. Offit
    • 1
  • R. W. Ellis
    • 2
  • D. Krah
    • 2
  • A. R. Shaw
    • 2
  • J. J. Eiden
    • 2
  • M. Pichichero
    • 3
  • J. J. Treanor
    • 3
  1. 1.Department of PediatricsUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Merck Research LaboratoriesWest PointUSA
  3. 3.School of MedicineUniversity of RochesterNew YorkUSA
  4. 4.Division of Infectious DiseasesChildren’s Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations